COGS step-change plan
Your plan is $137,556 a released patient. The typical commercial lot on this bill is $137,556. Each lever below is a current or published advance. Turn on the ones worth pursuing. Leave off the ones whose science or compliance risk is too high for the dollars they return. The aspiration is $10,000. This sketch does not force the bill to land there.
The three positions this plan starts from
This plan $137,556
Taken off the typical lot $0
Still above the aspiration $127,556
Cycle and failure 21d · 10%
Typical lot $137,556 Aspiration $10,000
This plan sits 0% of the way from the typical lot to $10,000.
Typical lot Reasonable only Ambitious set In vivo sketch
Process
Integrated closed automation Platforms such as CliniMACS Prodigy, Lonza Cocoon, and cartridge systems such as Cellares Cell Shuttle already run selection through harvest as a closed, automated sequence. A 2026 manufacturing review treats these as the current devices for one patient per instrument.
Fewer attended hours and fewer failed setups. Specialized single-use kits go up. Culture duration stays.
Reasonable Alone, $10,183 off the typical lot. $10,183 off once the other selected levers are on.
The devices exist and are in clinical use. The cost move on this bill is real and modest.
One-to-three-day manufacture Rapid programs keep the cells ex vivo for about one to three days instead of one to two weeks, to preserve a less differentiated phenotype and to reach infusion sooner. The same 2026 review describes this as process acceleration, not as a faster version of the standard expansion.
Expansion occupation, feeds, and cytokine drop with the shorter culture. Failure risk is higher because dose and phenotype are less proven at commercial scale.
Ambitious Alone, $17,283 off the typical lot. $17,283 off once the other selected levers are on.
Clinical programs exist. It is not the process approved products run today, and it can raise the chance a lot misses its dose.
Skip magnetic selection Some rapid workflows start from the washed collection and drop CD4/CD8 bead selection, which the 2026 review lists as a simplification under study.
Most of the selection resin leaves the bill. The starting population is less controlled.
Ambitious Alone, $5,988 off the typical lot. $5,988 off once the other selected levers are on.
Worth a development program. Myeloid cells and a drifting CD4/CD8 mix are the quality risk.
Point of care in an isolator A 2025 Frontiers paper describes isolator-based manufacture next to the clinic, with a fresh product and a rapid sterility method, so the lot does not take a cryogenic courier across the country.
Inbound and outbound couriers shrink. The vector and the culture do not.
Ambitious Alone, $2,406 off the typical lot. $2,406 off once the other selected levers are on.
The dollar move is the logistics, which are a small part of this bill. Hospital environments and a distributed quality system are the larger risk.
Materials
Less vector per dose A more efficient transduction, a smaller culture volume, or a suspension producer line uses less lentiviral or retroviral vector. The gene-transfer method stays viral, which is what approved products use.
The vector line falls by about half. The rest of the process stays.
Reasonable Alone, $26,667 off the typical lot. $26,667 off once the other selected levers are on.
A development target a plant can own. Half is an illustrative specification, not a quoted vector price.
Non-viral gene transfer Electroporation of a plasmid, transposon, or RNA, including closed workflows such as Cocoon with a Nucleofector, is published as a way around GMP viral-vector cost, slot time, and lead time. Lonza’s own note puts that viral-vector pain in the hundreds of thousands of dollars and many months.
The viral vector line is replaced by an illustrative nucleic-acid and electroporation cost, about 12% of the commercial vector on this bill.
Ambitious Alone, $44,874 off the typical lot. $44,874 off once the other selected levers are on.
Durable expression, insertion site, and the regulatory file are open. If this is on, the cheaper-virus lever no longer applies.
Quality
Rapid microbiological release Compendial sterility is a 14-day test. EU GMP for ATMPs already allows a rapid method when the product cannot wait. USP published an ATP-bioluminescence chapter for short shelf-life products in 2025. Growth-based rapid tests are reported in a few days; solid-phase cytometry is reported in hours after preparation.
The release hold and the contract sterility line shrink. Identity, purity, and potency testing remain.
Reasonable Alone, $14,425 off the typical lot. $14,425 off once the other selected levers are on.
A method a quality unit can validate for a short-dated product. Slow-growing organisms and cell-derived background are the work.
Automated release assays and an electronic record Parallel automated assay platforms and an electronic batch record cut manual QC handling and transcription. A 2025 review of rapid manufacture notes that identity and potency on a very young cell population are still the hard assays.
QC labor and a slice of the release occupation come down. The assay materials stay.
Reasonable Alone, $3,040 off the typical lot. $3,040 off once the other selected levers are on.
The workflow is buildable. Potency that predicts clinical effect, especially after a one-day process, is not solved by the instrument.
Product
In vivo CAR, no ex vivo lot Lipid nanoparticles and mRNA are being explored so the receptor is formed in the patient and the plant never holds a cell lot. The 2026 review treats this as a different manufacturing strategy, not as a shorter version of the autologous process.
Ex vivo unit operations drop out. What remains is an illustrative drug-substance, release, and delivery cost. The other process levers pause.
Unrealistic Alone, $105,632 off the typical lot. $105,632 off once the other selected levers are on.
This is a different medicine. It is not a plan for the plant that makes today’s autologous product, and it is not a number from a commercial cost study.
What the plan is using
No step-change levers yet. The figure above is the typical commercial lot. Reasonable only is the set a plant can pursue without changing the medicine. The ambitious set pulls the shorter process, the skipped selection, and non-viral transfer. In vivo is a different product.
Closed automation, rapid manufacture, and the limits of in-process analytics are reviewed in Journal of Biological Engineering (2026). Non-viral transfer on a closed device is described by Lonza for Cocoon and Nucleofector. Electroporation platforms and point-of-care systems are reviewed in a 2025 manufacturing survey. Rapid microbiology for short shelf-life products includes the USP ATP-bioluminescence chapter published in 2025, and isolator-based point-of-care manufacture is described in Frontiers in 2025. Dollar effects are moves on this illustrative bill.
Journal of Biological Engineering, 2026 · Lonza, Cocoon and Nucleofector · Cost-effective manufacturing survey, 2025 · USP ATP-bioluminescence, 2025 · Isolator point of care, 2025
The work after the sketch
A detailed cost model, and a glidepath that tracks plan against actual. This page shows which levers move an illustrative bill, and which ones buy little for the risk. The product a team pays for is the same structure on your vector, your resin, your cycle, and your failure rate, tied to a project record. Each lever you keep gets a plan cost and a date. Actual cost and actual cycle are entered as the work lands. The record shows whether the long-term price is still ahead, and which lever fell behind.
That tool is not on this site yet. The sketch is. The model and the glidepath are the engagement.